PROBLEM TO BE SOLVED: To provide methods for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.SOLUTION: A crystalline hydrate of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide is provided. Preferably, the hydrate is a hemihydrate. Preferably, the crystalline hydrate has an X-ray powder diffraction pattern characterized by peaks at 13.4±0.2, 15.1±0.2, and 21.7±0.2°2θ when measured at about 25°C with monochromatic Kα1 radiation.SELECTED DRAWING: None
- 출원번호 : 2025133176
- 출원인 : ABBVIE INC
- 특허번호 :
- IPC : C07D-487/14(2006.01);A61K-031/4985(2006.01);A61P-001/04(2006.01);A61P-017/06(2006.01);A61P-019/08(2006.01);A61P-017/02(2006.01);A61P-017/14(2006.01);A61P-037/08(2006.01);A61P-037/02(2006.01);A61P-043/00(2006.01);A61K-047/12(2006.01);A61K-047/38(2006.01);A61K-009/06(2006.01);